Agenus finalized a $141 million strategic collaboration with Zydus Lifesciences to accelerate global development and commercial readiness for its BOT+BAL immunotherapy combination. The agreement provides Agenus with committed U.S. biologics manufacturing capacity and authorized early‑access pathways while granting Zydus exclusive rights in India and Sri Lanka. Agenus emphasized the transaction strengthens its balance sheet and secures manufacturing at a critical point for its Phase III program in MSS colorectal cancer; facilities will be transferred into a Zydus subsidiary named Zylidac Bio.